Table 2

Reported adherence by patients to their new medicine (measured using the NMS question and Morisky Eight-Item Medication Adherence Scale (MMAS-8) and intention-to-treat analysis of the intervention as a predictor of adherence at weeks 10 and 26—frequency counts, unadjusted, adjusted and imputed ORs

Intention-to-treat analysis at week 10 or 26 follow-upAdherent patients/total responses, n (%), P valueModel 1* (naïve)
OR (95% CI, P value)
Model 2 (main/adjusted)
OR (95% CI, P value)
Model 3 (imputation)
OR (95% CI, P value)
10-week follow-up: adherence as assessed by NMS question (n=378)
Normal practice115/190 (60.5)1.001.001.00
NMS intervention133/188 (70.7), 0.0371.58 (1.03 to 2.42, 0.037)1.67 (1.06 to 2.62, 0.027)1.62 (1.04 to 2.53, 0.032)
26-week follow-up: adherence as assessed by NMS question (n=327)
Normal practice97/170 (57.1)1.001.001.00
NMS intervention103/157 (65.6), 0.1131.44 (0.92 to 2.25, 0.114)1.50 (0.93 to 2.44, 0.095)1.50 (0.89 to 2.51, 0.127)
Secondary outcomes (adherence as assessed by MMAS-8)
10-week follow-up adherence MMAS-8 (n=267)
Normal practice85/143 (59.4)1.001.001.00
NMS intervention89/124 (71.8), 0.0351.74 (1.04 to 2.90, 0.036)1.88 (1.06 to 3.34, 0.030)1.77 (0.96 to 3.28, 0.068)
26-week follow-up adherence MMAS-8 (n=223)
Normal practice70/124 (56.5)1.001.001.00
NMS intervention63/99 (63.6), 0.2771.35 (0.79 to 2.32, 0.278)1.60 (0.84 to 3.06, 0.153)1.43 (0.70 to 2.91, 0.320)
  • *Model 1 (naïve): simple logistic regression model. Model 2 (main/adjusted): logistic regression model adjusted for recruiting pharmacy, disease, age, sex and medication count. Model 3 (imputation): adjusted logistic regression model taking imputation of missing data into account.

  • NMS, New Medicine Service.